UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Grows Holdings in XBiotech Inc. (NASDAQ:XBIT)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in XBiotech Inc. (NASDAQ:XBIT) by 2.2% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 253,770 shares of the biopharmaceutical company’s stock after purchasing an additional 5,500 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.83% of XBiotech worth $1,962,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in XBIT. American Century Companies Inc. purchased a new position in XBiotech in the 2nd quarter valued at about $393,000. Bank of New York Mellon Corp lifted its holdings in XBiotech by 102.9% in the 2nd quarter. Bank of New York Mellon Corp now owns 98,314 shares of the biopharmaceutical company’s stock valued at $505,000 after purchasing an additional 49,863 shares in the last quarter. BNP Paribas Financial Markets lifted its holdings in XBiotech by 184.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 40,040 shares of the biopharmaceutical company’s stock valued at $310,000 after purchasing an additional 25,987 shares in the last quarter. Rhumbline Advisers lifted its holdings in XBiotech by 2,568.5% in the 2nd quarter. Rhumbline Advisers now owns 20,094 shares of the biopharmaceutical company’s stock valued at $103,000 after purchasing an additional 19,341 shares in the last quarter. Finally, MetLife Investment Management LLC purchased a new position in XBiotech in the 3rd quarter valued at about $94,000. 55.70% of the stock is currently owned by hedge funds and other institutional investors.

XBiotech Trading Up 0.3 %

NASDAQ:XBIT opened at $6.95 on Monday. The firm has a market cap of $211.84 million, a price-to-earnings ratio of -6.44 and a beta of 1.41. The company’s 50-day moving average is $7.13 and its two-hundred day moving average is $6.70. XBiotech Inc. has a 12-month low of $3.81 and a 12-month high of $9.96.

XBiotech Company Profile

XBiotech Inc, a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation.